- Home
- NMAI vs KRRO Comparison
NMAI vs KRRO Comparison
Compare NMAI & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMAI
- KRRO
- Stock Information
- Founded
- NMAI 2021
- KRRO 2014
- Country
- NMAI United States
- KRRO United States
- Employees
- NMAI N/A
- KRRO N/A
- Industry
- NMAI Investment Managers
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- NMAI Finance
- KRRO Health Care
- Exchange
- NMAI Nasdaq
- KRRO Nasdaq
- Market Cap
- NMAI 430.5M
- KRRO 490.1M
- IPO Year
- NMAI N/A
- KRRO 2019
- Fundamental
- Price
- NMAI $12.19
- KRRO $48.04
- Analyst Decision
- NMAI
- KRRO Strong Buy
- Analyst Count
- NMAI 0
- KRRO 7
- Target Price
- NMAI N/A
- KRRO $133.83
- AVG Volume (30 Days)
- NMAI 74.8K
- KRRO 121.8K
- Earning Date
- NMAI 01-01-0001
- KRRO 11-12-2024
- Dividend Yield
- NMAI 13.14%
- KRRO N/A
- EPS Growth
- NMAI N/A
- KRRO N/A
- EPS
- NMAI 0.64
- KRRO N/A
- Revenue
- NMAI N/A
- KRRO N/A
- Revenue This Year
- NMAI N/A
- KRRO N/A
- Revenue Next Year
- NMAI N/A
- KRRO N/A
- P/E Ratio
- NMAI $19.03
- KRRO N/A
- Revenue Growth
- NMAI N/A
- KRRO N/A
- 52 Week Low
- NMAI $10.60
- KRRO $30.01
- 52 Week High
- NMAI $12.55
- KRRO $98.00
- Technical
- Relative Strength Index (RSI)
- NMAI 27.78
- KRRO 49.74
- Support Level
- NMAI $12.79
- KRRO $41.14
- Resistance Level
- NMAI $12.89
- KRRO $51.95
- Average True Range (ATR)
- NMAI 0.09
- KRRO 5.75
- MACD
- NMAI -0.06
- KRRO 0.44
- Stochastic Oscillator
- NMAI 1.25
- KRRO 66.74
About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment strategy uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.